Company profile: Woolsey Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of investigational oral fasudil (BRAVYL) for indications including dementia-related wandering, Progressive Supranuclear Palsy, Corticobasal Syndrome, and Amyotrophic Lateral Sclerosis; conducts phase 2a studies (FOUND, REAL, ROCKIT-1) to evaluate efficacy, safety, and biomarkers; and maintains an expanded access policy for serious or life-threatening conditions.
Products and services
- BRAVYL: Oral fasudil version engineered for dementia-related wandering, Progressive Supranuclear Palsy, Corticobasal Syndrome, and Amyotrophic Lateral Sclerosis indications
- ROCKIT-1 Study: Biomarker-focused clinical assessment measuring BRAVYL’s effects on neurodegeneration biomarkers and clinical outcomes in PSP and CBS patients
- REAL Study: Phase 2a clinical trial evaluating BRAVYL’s safety, tolerability, and patient impact in ALS over a 24-week period
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Woolsey Pharmaceuticals
Vactech
HQ: Finland
Website
- Description: Provider of early-stage product candidates focused on Type 1 Diabetes, Celiac Disease, Asthma & Allergy, and diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vactech company profile →
Kinarus
HQ: Switzerland
Website
- Description: Provider of biopharmaceutical therapies targeting stress-related inflammatory processes. Develops KIN001, a pamapimod/pioglitazone combination with anti-inflammatory, anti-fibrotic, and antiviral activities, in Phase 2 trials for hospitalized COVID-19 (acute and long-term), wet AMD (reducing anti-VEGF injection frequency), and IPF (reducing lung fibrosis).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kinarus company profile →
Santarus
HQ: United States
Website
- Description: Provider of specialty biopharmaceutical products focused on acquiring, developing and commercializing proprietary therapies that address the needs of patients treated by physician specialists; current commercial efforts encompass five products, including UCERIS (budesonide) extended release tablets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Santarus company profile →
Ascendis Pharma
HQ: United States
Website
- Description: Provider of the TransCon prodrug technology platform, which transiently conjugates an inert carrier to a parent drug for systemic or localized release, and a pipeline of investigational therapies: TransCon hGH for growth hormone deficiency, TransCon PTH for hypoparathyroidism, TransCon CNP for achondroplasia, and oncology candidates TransCon TLR7/8 Agonist and TransCon IL-2 β/γ.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ascendis Pharma company profile →
Halia Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for inflammatory and neurodegenerative disorders, including HT-6184, a novel NEK7/NLRP3 inhibitor in Phase II for lower-risk myelodysplastic syndromes and post-procedure diagnostic biomarkers of inflammation and pain. Pipeline includes NEK7 inhibitors to block NLRP3 inflammasome assembly and LRRK2 inhibitors for diseases such as Parkinson's and Alzheimer's.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Halia Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Woolsey Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Woolsey Pharmaceuticals
2.2 - Growth funds investing in similar companies to Woolsey Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Woolsey Pharmaceuticals
4.2 - Public trading comparable groups for Woolsey Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →